Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18096762 | 0.92 | SCN9A (0.84) | SCN9ASCN5ASCN10A | |
| SCHEMBL18096617 | 0.92 | SCN9A (0.85) | SCN9ASCN5AAKT1 | |
| SCHEMBL18096695 | 0.86 | SCN9A (0.76) | SCN9ASCN5ASCN10A | |
| SCHEMBL18096618 | 0.86 | SCN9A (0.74) | SCN9ASCN5A | |
| SCHEMBL20481832 | 0.85 | SCN9A (0.75) | SCN9ASCN5ASCN10A | |
| SCHEMBL18096708 | 0.84 | SCN9A (0.84) | SCN9ASCN5A | |
| SCHEMBL18096704 | 0.84 | SCN9A (1.00) | SCN9ASCN5AAKT1 | |
| SCHEMBL18096684 | 0.83 | SCN9A (1.00) | SCN9ASCN5AAKT1 | |
| SCHEMBL18096594 | 0.83 | SCN9A (1.00) | SCN9ASCN5ASCN10A | |
| SCHEMBL18096581 | 0.82 | SCN9A (0.71) | SCN9ASCN5ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | claimed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | claimed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-3274335-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150971-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, SCN1A, SCN3A | SCN9A 31/4885SCN5A 4/4885AKT1 2222/4885 |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | SCN1B, SCN1A, SCN3A | SCN9A 29/4885SCN5A 4/4885AKT1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.